BridgeBio is a commercial-stage biopharmaceutical company focused on genetic diseases. Its primary product is Attruby (acoramidis), an oral small molecule that treats transthyretin amyloid cardiomyopathy (ATTR-CM) — a progressive heart disease where the TTR protein misfolds and deposits in the heart. Attruby works by stabilizing the TTR protein, preventing amyloid formation. The FDA approved Attruby in November 2024, and BridgeBio sells it directly in the U.S. through specialty pharmacies, while Bayer and Alexion handle commercialization in Europe and Japan, respectively. BridgeBio earns royalties on ex-U.S. sales plus milestone payments from partners. Beyond Attruby, BridgeBio has three late-stage pipeline candidates, each with positive Phase 3 data: infigratinib for achondroplasia (a rare form of dwarfism), encaleret for a rare calcium metabolism disorder, and BBP-418 for a rare inherited muscle disease — with NDA submissions planned across all three in 2026. BridgeBio's business model centers on selling specialty drugs to rare disease patients at prices designed to minimize payer friction. Attruby carries high gross margins typical of an oral small molecule, and BridgeBio outsources manufacturing entirely to contract manufacturers. The main costs are the sales force, marketing, patient support programs, and ongoing R&D. BridgeBio's R&D model emphasizes capital efficiency through a decentralized hub-and-spoke structure, and management states the company advances programs to proof of concept for an average of less than $40M per program.